Streetbeat News

Regulatory

CELZ

Creative Medical Technology Holdings Inc (NASDAQ:CELZ) saw its stock surge after receiving FDA authorization for CELZ-201, a therapy aimed at managing abnormal glucose tolerance and preventing Type 1 diabetes in high-risk individuals. This groundbreaking therapy represents a significant advancement in personalized medicine for diabetes management. Additionally, CELZ received Orphan Drug Designation for CELZ-101, ImmCelz, to prevent allograft rejection in pancreatic islet cell transplantation for Type 1 diabetes patients. CELZ shares rose 34.50% to $6.40.

Portfolio Pulse from Vandana Singh

March 07, 2024 | 6:16 pm

ETH-USD

On Wednesday, 16,557.91 Ether (ETH) worth approximately $64.12 million was burned, permanently removing it from circulation. This action follows the Ethereum blockchain's EIP-1159 upgrade, which introduced a variable base fee for transactions that is burned, contributing to a decrease in Ether's supply. The Ethereum network is currently issuing new Ether at a 4% annual rate, expected to drop to 0.5-1% with the Ethereum 2.0 upgrade, potentially making ETH a deflationary currency. The net annualized issuance rate for Ether was -21.99% yesterday.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 6:00 pm

AAPL

VGK

EU Industrial Chief Thierry Breton has announced that the EU will prioritize investigating Apple's decision to terminate Epic Games' developer account. This move comes amid ongoing tensions between Apple and Epic Games over app store policies and fees.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 5:50 pm

MDT

The FDA has classified Medtronic Neurosurgery's recall of its Duet External Drainage and Monitoring System Catheter Tubing as a Class I recall due to the risk of catheter disconnection. This issue has already resulted in 26 reported injuries. The recall highlights a significant safety concern for patients using the device.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 5:49 pm

ASML

EZU

IFNNY

ULE

The European Central Bank (ECB) maintained interest rates at 4%, with no policy change for the fourth consecutive month, mirroring the Federal Reserve's approach. ECB President Christine Lagarde emphasized maintaining current policy levels to achieve a 2% inflation target. The ECB revised its inflation forecast to 2.3% for this year, down from 2.7%, and to 2% in 2025, from 2.1%. Markets reacted positively, with significant gains for ASML Holding NV and Infineon Technologies AG, as well as increases in the iShares MSCI Eurozone ETF (EZU) and the ProShares Ultra Euro ETF (ULE).

Portfolio Pulse from Neil Dennis

March 07, 2024 | 5:44 pm

ATAI

ATAI Life Sciences shares are trading higher, potentially in response to MindMed receiving FDA Breakthrough Therapy Designation for its MM120 program in generalized anxiety disorder.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 5:42 pm

EWC

UNG

The Canada Energy Regulator has approved the first compressed natural gas facility in the Northwest Territories, marking a significant step in the region's energy development. This decision could influence the energy sector, particularly companies and ETFs involved in natural gas.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 5:34 pm

F

FXI

GM

SPY

STLA

Three Democratic U.S. Senators have urged President Biden to increase tariffs on Chinese imported autos, expressing concerns that these imports could threaten the American automotive manufacturing sector. The senators' appeal highlights the potential risks to domestic industry competitiveness and job security in the face of growing imports from China.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 5:22 pm

GSK

GSK plc announced positive results from the DREAMM-8 phase III trial for Blenrep in combination therapy for multiple myeloma, showing significant improvement in progression-free survival compared to standard care. This comes after the withdrawal process of Blenrep's U.S. marketing authorization initiated in November 2022 due to a failed confirmatory trial. The company plans to present detailed findings at a future medical congress and share them with regulatory authorities.

Portfolio Pulse from Vandana Singh

March 07, 2024 | 5:18 pm

SPY

The hearing of Fed Chair Powell at the Senate Banking Committee has concluded.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 5:09 pm